Skip Navigation

Cardiovascular Research 2001 49(2):351-360; doi:10.1016/S0008-6363(00)00259-5
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Amos, G. J
Right arrow Articles by Carlsson, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amos, G. J
Right arrow Articles by Carlsson, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potential

Gregory J Amosa, Christina Abrahamssona, Göran Dukera, Luc Hondeghemb, Mattias Palmera and Leif Carlssona,*

aAstraZeneca Research & Development Mölndal, Integrative Pharmacology, S-43183 Mölndal, Sweden
bHPC N.V., Oostende, Belgium

* Corresponding author. Tel.: +46-31-776-1682; fax: +46-31-776-3766 leif.g.carlsson{at}astrazeneca.com

Objectives: To study the blocking effects of H 345/52 on ionic currents of rabbit ventricular myocytes and how these features translate into a proarrhythmic potential. Methods: The single electrode voltage clamp technique was used to study the effects of H 345/52 on the rapid component of the delayed rectifying potassium current, IKr, and the L-type calcium current (ICa). Differential effects of H 345/52 and almokalant on APD prolongation were studied in a rabbit Purkinje fibre/ventricular muscle preparation. The temporal variability of the action potential duration (APD) and its relation to proarrhythmias was examined in Langendorff-perfused rabbit hearts administered H 345/52 or almokalant. Anaesthetised, methoxamine-sensitised rabbits were used to assess the propensity of intravenous H 345/52 and ibutilide to induce torsades de pointes (TdP). Results: H 345/52 potently blocked IKr (IC50=40 nM) without consequential use-dependency. The ICa was also blocked, but at higher concentrations (IC50=1.3 µM). Block of ICa was markedly frequency-dependent (positive) and influenced by membrane potential, such that H 345/52 was more effective following clamp steps from plateau potentials than from –80 mV. In the Purkinje fibre–ventricular muscle preparation, almokalant prolonged the Purkinje fibre APD preferentially, whereas H 345/52 homogeneously prolonged APD in both tissue types. In the perfused rabbit heart, H 345/52 (1 µM) and almokalant (0.3 µM) prolonged APD to a similar degree but increased the temporal variability of APD differently, from 3±0.4 ms in control hearts to 8±1.2 ms and to 38±7.5 ms (P<0.001 vs. H 345/52), respectively. Unequivocal early after-depolarisations were seen in 5/6 almokalant-perfused hearts but in no heart administered H 345/52 (P<0.05). In anaesthetised rabbits, H 345/52 (17.4 µmol/kg) or ibutilide (2.6 µmol/kg maximum), maximally lengthened the QT interval from 133±4.5 to 177±8.0 ms and from 125±5.1 to 166±9.3 ms (P<0.001, n = 8). However, whereas ibutilide induced TdP in all animals at 0.06±0.009 µmol/kg, H 345/52 did not induce TdP (P = 0.0002) at up to 17.4 µmol/kg. Conclusions: H 345/52 blocks IKr with high potency and ICa with somewhat lower potency and was found to delay ventricular repolarisation without substantially increasing temporal or spatial dispersion and without inducing early after-depolarisations or TdP.

KEYWORDS Antiarrhythmic agents; K-channel; Long QT syndrome; QT dispersion; Ventricular arrhythmias


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
P. M.R. Orth, J. C. Hesketh, C. K.H. Mak, Y. Yang, S. Lin, G. N. Beatch, A. M. Ezrin, and D. Fedida
RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents
Cardiovasc Res, June 1, 2006; 70(3): 486 - 496.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G.-J. Chang, M.-J. Su, S.-C. Kuo, T.-P. Lin, and Y.-S. Lee
Multiple Cellular Electrophysiological Effects of a Novel Antiarrhythmic Furoquinoline Derivative HA-7 [N-Benzyl-7-methoxy-2,3,4,9-tetrahydrofuro[2,3-b]quinoline-3,4-dione] in Guinea Pig Cardiac Preparations
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 380 - 391.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
L. Carlsson
Drug-induced torsade de pointes: the perspectives of industry
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K114 - K120.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.